Delivery Order SPE2DB22D2007-SPE2DB24FJ4NE
Award Date
7/25/24
Potential Completion Date
8/15/24
Potential Value
$46K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $47,834.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, issued by the Defense Logistics Agency (DLA), was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 24, 2025 and is a firm fixed-price contract. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $119,585.40 and a completion date of December 26, 2024. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $72,115.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medical product. The contract has an ultimate completion date of April 14, 2025 and was awarded on March 24, 2025. There is no set-aside designation associated with this contract....
This federal contract award, valued at $48,077.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 mg/10 ml vials, a specialty medication, to support federal healthcare programs. The contract has an ultimate completion date of March 12, 2025, and it is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside....
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $72,115.74 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract is not set aside and has a performance period ending on June 4, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $48,077.16 and a period of performance through May 14, 2025. The contract provides for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp...
This federal contract award, valued at $87,447.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of August 24, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $50,799.79 and is a Firm Fixed Price Delivery Order with an ultimate completion date of April 28, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This contract award to Amerisourcebergen Drug Corp (a major pharmaceutical distributor) is a Delivery Order (SPE2DB24FD7Z1) from the Defense Logistics Agency (DLA) Troop Support Medical. It is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a ceiling value of $115,590.40. The award has a period of performance through October 3, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...